| Name | Title | Contact Details |
|---|
Verséa Health is a diversified global healthcare company engaged in scientific discovery, development and commercialization of innovative products and services intended to diagnose, manage, and treat debilitating diseases.
We help you reach your savings targets and your patient experience goals by designing and delivering supplies and patient care products.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
APP Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Hemagen Diagnostics is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.